Treatment of Covid-19 Patients With High Dose of Ulinastatin

Abstract

Background No specific therapeutic agents or vaccines are available for the treatment of Coronavirus disease 2019 (Covid-19) yet. In this study, we aimed to assess the efficacy of high dose ulinastatin for patients with Covid-19.Methods Twelve patients hospitalized with confirmed SARS-CoV-2 infection were treated with high dose of ulinastatin beyond standard care. The changes of clinical manifestations, laboratory examinations and chest images were retrospectively analyzed. Results A total of 10 patients with severe Covid-19 and 2 patients with moderate Covid-19 received ulinastatin treatment. The average age of the patients was 68.0 ± 11.9 years, ranging from 48 to 87 years. Nine of 12 patients (75.0%) had one or more comorbidities. The most common symptoms on admission were fever (8/12, 66.7%), cough (5/12, 41.7%) and dyspnea (5/12, 41.7%). The percentage of lymphocytes was decreased in 41.7% of patients (5/12), and 58.3% of patients (7/12) had elevated hypersensitive C-reactive protein (CRP) levels (mean, 49.70 ± 77.70 mg/L). The white blood cell levels and the percentage of lymphocytes returned to normal in all of the patients, and CRP decreased significantly and returned to normal in 83.3% of patients (10/12; mean, 6.87 ± 6.63 mg/L) on the seventh day after ulinastatin treatment. Clinical symptoms were relieved synchronously. The peripheral oxygen saturation improved and 66.7% of the patients (8/12) did not need further oxygen therapy seven days after ulinastatin treatment. No patients required intensive care unit admission or mechanical ventilation. All patients revealed different degrees of absorption of pulmonary lesions after treatment. No obvious adverse events were observed.Conclusions Our preliminary data revealed that high dose of ulinastatin treatment was safe and showed a potential beneficial effect for patients with Covid-19.

Cytokine storm induced by SARS-CoV-2 infection: The spectrum of its neurological manifestations

“… [144] , [150] Ulinastatin May be a promising therapy at high doses, with clinical trials underway in China. [151] , [152] …”

Insights into the potential role of alpha1‐antitrypsin in COVID‐19 patients: Mechanisms, current update, and future perspectives

“…Moreover, it has significant anti‐oxidative effects through lowering the level of superoxide dismutase, malondialdehyde, justifying its clinical use in several disorders as the ARDS as it improves lung function, oxygenation, and eventually shortens the period of mechanical ventilations and total hospital stay. Interestingly, high doses of ulinastatin were recently administered via intravenous infusion and are being suggested to have a beneficial impact on patients with COVID‐19 12‐14 …”

A Generalized Overview of the Possible Pharmacotherapy and Treatments against SARS-CoV-2

“…Ulinastatin is a glycoprotein which extracted and purified from fresh human urine, the anti-inflammatory agent in our body that is used in the treatment of pancreatitis and acute circulatory failure, and for the cytokine storm for COVID-19 as well [14,[144][145][146][147]. Ulinastatin is a serine protease inhibitor with anti-inflammatory properties and has superb opportunities for the treatment of SARS-CoV2 infection, as it protects the vascular endothelium by blocking the generation and releases of inflammatory substances [144,147].…”